Adverse events reported in oncology clinical trials don’t always match what patients experience. What is behind this disconnect and is it possible to reconcile?

Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical ...

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...

Exelixis’ (EXEL) lead drug, Cabometyx, a tyrosine kinase inhibitor (TKI), maintains a dominant position for the treatment of ...

Immunotherapy is a revolutionary cancer treatment. It uses the body's immune system to fight cancer cells. This approach ...